v3.26.3
INVESTMENTS IN EQUITY SECURITIES
9 Months Ended
Sep. 30, 2026
INVESTMENTS IN EQUITY SECURITIES  
INVESTMENTS IN EQUITY SECURITIES

NOTE 9 – INVESTMENTS IN EQUITY SECURITIES

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

As of beginning of the period/year

 

 

2,027,540

 

 

 

1,265,166

 

Addition during the year

 

 

-

 

 

 

1,790,333

 

Disposal during the year

 

 

-

 

 

 

(1,004,428 )

Fair value (loss)/gain

 

 

-

 

 

 

(93,965 )

Foreign exchange translation

 

 

(1,117)

 

 

70,434

 

As of end of the period/year

 

 

2,026,423

 

 

 

2,027,540

 

 

For the nine-month periods ended September 30, 2026 and 2025, the net fair value gain/(loss) on the investments in equity securities was $nil and $(91,243), respectively, recorded in administrative expenses and other income of the Condensed Consolidated Statements of Operations and Comprehensive Income/(Loss).

 

 The investments in equity securities consist of the following shares:

 

 

 

As of

 

 

 

September 30,

 

 

December 31,

 

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

Investment in equity securities without readily determined fair value:

 

 

 

 

 

 

Malaysia

 

 

245,249

 

 

 

246,366

 

Singapore

 

 

1,781,174

 

 

 

1,781,174

 

 

 

$2,026,423

 

 

$2,027,540

 

 

Equity Securities Without Readily Determinable Fair Values

 

The Company’s investments in equity securities without readily determinable fair values consist of investments in privately held companies and totaled $2,026,423 and $2,027,540 as of September 30, 2026 and December 31, 2025, respectively.

 

These investments are accounted for in accordance with ASC 321, Investments—Equity Securities, using the measurement alternative, under which such securities are measured at cost, less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.

 

The Company evaluates these investments for impairment on a quarterly basis by performing a qualitative assessment to determine whether the fair value of an investment is less than its carrying amount. If an impairment is identified, the investment is written down to its fair value, with the loss recognized in earnings. In addition, the carrying value of these investments is adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.

 

Because these investments are in privately held companies and lack observable market prices, the determination of fair value for impairment assessments requires significant judgment. When such investments are remeasured due to impairment or observable price changes, the resulting fair value measurements are classified within Level 3 of the fair value hierarchy.

 

For fiscal year 2025, the Company issued 392,329 shares of common stock at a value of $1,781,174 to Fidelion Diagnostics Pte. Ltd (“Fidelion”) as consideration for the Company’s subscription of Fidelion shares. This transaction formed part of the conditions under the previously disclosed Share Subscription and Shareholders’ Agreement entered into with Fidelion and Tongshu Biotechnology (Hong Kong) Co., Limited.